Michael Garnreiter Sells 1,000 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the sale, the director now owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Garnreiter also recently made the following trade(s):

• On Monday, September 16th, Michael Garnreiter sold 1,000 shares of Axon Enterprise stock. The stock was sold at an average price of $380.99, for a total value of $380,990.00.

Axon Enterprise Trading Down 0.1 %

NASDAQ AXON traded down $0.29 during trading on Wednesday, hitting $433.83. 375,993 shares of the company’s stock traded hands, compared to its average volume of 523,883. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. Axon Enterprise, Inc. has a 12-month low of $199.29 and a 12-month high of $440.89. The stock has a fifty day moving average of $384.24 and a two-hundred day moving average of $329.30. The firm has a market cap of $32.78 billion, a P/E ratio of 114.54, a PEG ratio of 11.49 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter last year, the business posted $0.80 EPS. The firm’s revenue for the quarter was up 34.5% compared to the same quarter last year. As a group, sell-side analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Barclays increased their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities boosted their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Robert W. Baird increased their price target on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective for the company. Finally, Craig Hallum lifted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $365.38.

Institutional Trading of Axon Enterprise

Institutional investors and hedge funds have recently bought and sold shares of the stock. Avantax Advisory Services Inc. lifted its holdings in shares of Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after acquiring an additional 40 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Axon Enterprise during the first quarter worth $931,000. Zurich Insurance Group Ltd FI grew its stake in Axon Enterprise by 1.9% in the second quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock valued at $60,324,000 after purchasing an additional 3,832 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after acquiring an additional 22,013 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Axon Enterprise by 21.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock worth $2,693,000 after buying an additional 1,634 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.